Elevated 18F-FDG uptake in non-metastatic lymph nodes of POLE-mutated endometrial cancer on PET/CT
European Journal of Radiology · 2026
DOI: 10.1016/j.ejrad.2025.112620 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Radiology, 2026. Verfasst von Maho Kurihara und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Positron Emission Tomography Computed Tomography, Endometrial Neoplasms, Lymph Nodes. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
PURPOSE: DNA polymerase epsilon (POLE) exonuclease domain-mutated endometrial cancer (EC) is associated with a favorable prognosis and significant immune cell infiltration. Cancers with significant immune cell infiltration often exhibit higher maximum standardized uptake value (SUVmax) on 18F-fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT). This study aimed to evaluate the correlation between POLE status and FDG-PET/CT imaging in patients with EC. METHODS: This retrospective study enrolled 102 patients (mean age, 56.2 ± 11.8 years) with EC who underwent preoperative FDG-PET/CT between July 2018 and August 2023. Patients were categorized into molecular subtypes based on molecular profiling. SUVmax of the primary tumor and lymph nodes was measured, and correlations with molecular subtypes were examined. RESULTS: The SUVmax in the primary tumor of POLE-mutated ECs was higher than that in non-POLE-mutated ECs (mean ± SD, 13.21 ± 4.78 vs 9.82 ± 3.78; p = 0.001). Multiple regression analysis showed that POLE status was associated with SUVmax in primary tumors (B = 2.30, p = 0.031). The SUVmax in non-metastatic lymph nodes of POLE-mutated ECs was higher than that in non-POLE-mutated ECs (median SUVmax, 1.31 [IQR, 1.05-2.21] vs. 1.06 [IQR, 0.91-1.20]; p = 0.003). Multiple regression analysis revealed that POLE status was the only factor associated with SUVmax in non-metastatic lymph nodes (B = 0.339, p = 0.046), while age, BMI, blood glucose level, histological type, and primary tumor size showed no significant association. CONCLUSION: Patients with POLE-mutated EC exhibit high SUVmax in primary tumors and also tend to show elevated uptake in non-metastatic lymph nodes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Keio University School of Medicine, Tokyo, Japan.
- Department of Radiology, Keio University School of Medicine, Tokyo, Japan. Electronic address: iwabuchi@rad.med.keio.ac.jp.
- Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
- Genomics Unit, Keio Cancer Center, Keio University School of Medicine, Tokyo, Japan.
Förderung
- Japan Society for the Promotion of Science
- Japan Agency for Medical Research and Development
Zitieren
APA
Kurihara, M., Iwabuchi, Y., Yamada, Y., Shimizu, A., Yoshimura, T., Sakai, K., Chiyoda, T., Nakamura, K., Nishihara, H., Yamagami, W., & Jinzaki, M. (2026). Elevated 18F-FDG uptake in non-metastatic lymph nodes of POLE-mutated endometrial cancer on PET/CT. European Journal of Radiology. https://doi.org/10.1016/j.ejrad.2025.112620
Vancouver
Kurihara M, Iwabuchi Y, Yamada Y, Shimizu A, Yoshimura T, Sakai K, et al. Elevated 18F-FDG uptake in non-metastatic lymph nodes of POLE-mutated endometrial cancer on PET/CT. European Journal of Radiology. 2026. doi:10.1016/j.ejrad.2025.112620
BibTeX
@article{Kurihara2026,
author = {Kurihara, Maho and Iwabuchi, Yu and Yamada, Yoshitake and Shimizu, Atsushi and Yoshimura, Takuma and Sakai, Kensuke and Chiyoda, Tatsuyuki and Nakamura, Kohei and Nishihara, Hiroshi and Yamagami, Wataru and Jinzaki, Masahiro},
title = {Elevated 18F-FDG uptake in non-metastatic lymph nodes of POLE-mutated endometrial cancer on PET/CT},
journal = {European Journal of Radiology},
year = {2026},
doi = {10.1016/j.ejrad.2025.112620}
}
EUVIMED